Enhanced Pharmaceutical Compositions for Viral Infections

This inventive concept discloses novel pharmaceutical compositions comprising sulfur-containing nucleosides conjugated to lipids or sphingolipids, with added stabilizing agents, permeation enhancers, or mucoadhesive agents, to improve the treatment of viral infections.

The original patent disclosed pharmaceutical compositions comprising sulfur-containing nucleosides, but these compositions had limitations in terms of shelf life, stability, and bioavailability. The new inventive concept addresses these limitations by introducing conjugate compounds linked to lipids or sphingolipids, which enhance the delivery and efficacy of the nucleoside analogs.

The new pharmaceutical compositions comprise conjugate compounds of Formula Im, where the conjugate compound is linked to a lipid or sphingolipid via a phosphorus oxide. The compositions further include a stabilizing agent, such as antioxidants, chelating agents, or pH buffers, to enhance the shelf life and stability of the composition. Additionally, the compositions may include a permeation enhancer to facilitate the delivery of the conjugate compound across the cell membrane, or a mucoadhesive agent to enhance the bioavailability and retention of the composition at the site of infection.

The new inventive concept introduces the conjugation of sulfur-containing nucleosides to lipids or sphingolipids, which is a novel and non-obvious improvement over the original patent. The addition of stabilizing agents, permeation enhancers, or mucoadhesive agents provides further enhancements to the composition, making it more effective and efficient in treating viral infections.

Other embodiments of the inventive concept may include varying the type of lipid or sphingolipid used, or modifying the phosphorus oxide linker. Additionally, the compositions may be formulated for specific routes of administration, such as oral, injectable, or topical.

The enhanced pharmaceutical compositions have significant commercial potential in the treatment of viral infections, particularly in the areas of antiviral therapy and vaccine development. The target market includes pharmaceutical companies, research institutions, and healthcare providers.